Bayer AG's pharmaceuticals division has announced a strategic focus on reducing debt over the next two to three years, with no plans for major acquisitions during this period. This statement was made by the head of the division in an interview released on January 14, 2025. Concurrently, Bayer's growth strategy in pharmaceuticals is reportedly progressing well, with advancements in its pipeline. The updates were highlighted during the 43rd Annual J.P. Morgan Healthcare Conference, where the company discussed its business and pipeline developments.